AngioDynamics Commences the RECOVER-AV Study of AlphaVac F1885 System to Treat Pulmonary Embolism
Shots:
- AngioDynamics has initiated the RECOVER-AV trial to assess the safety, efficacy & long-term functional effects of the AlphaVac MMA F1885 System for treating acute, intermediate-risk PE in the EU
- The efficacy 1EP includes reduction in the RV/LV ratio from baseline to 48hrs. while the safety 1EPs are the incidence of Major Adverse Events (MAEs) like device-related death or major bleeding within 7 days. Patients will be assessed for 12mos., with functional results evaluated at 30-days, 6 & 12mos.
- The trial follows the APEX-AV study, involving US patients (n=122), that showed the system’s safety and effectiveness in treating acute intermediate-risk PE, improving right ventricular function & reducing clot burden
Ref: AngioDynamics | Image: AngioDynamics
Related News:- AngioDynamics’ AlphaVac F18⁸⁵ System Gains the US FDA’s Clearance to Treat Pulmonary Embolism
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
